Eureka Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eureka Therapeutics, Inc.
Korean bioventure’s interim Phase IIa data for locoregional high-dose, autologous natural killer cell therapy in hepatocellular carcinoma in combination with HAIC look "promising," but further safety data awaited.
Deal Watch: Merck Looks To Technology Platform Partners For Cytokine Agonist Discovery, Drug Delivery
Plus deals involving Moderna/Metagenomi, Agomab/Origo, Selecta/Ginkgo, Teva/MODAG, Boehringer Ingelheim/Thoeris and X-Chem/ComInnex/Glamorous AI.
The intellectual property, also held by Eureka, may offer a new pathway for treating relapsed MM patients. Sorrento inks cancer partnerships with Karolinska Institutet and Mayo Clinic.
Plus recent deals involving BeiGene, Assembly Biosciences, Piramal, Medivant, Revitope, Junshi, JW Therapeutics, Eureka, Acepodia, Chiesi, Bayer, NewG Lab, AnHeart
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Eureka (Beijing) Biotechnology Co., Ltd.